SecBot SecBot
PRESS-RELEASE ·Filed Mar 5, 2026

CRMD

CorMedix, Inc.
BULLISH
Impact 8/10
Horizonweeks Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

The strong financial performance and robust cash position support the company’s 2026 outlook and buyback. Traders should monitor upcoming Phase 3 data for REZZAYO in Q2 2026 as a key catalyst.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$6.30
T+0 close · Mar 5, 2026 · via day close
Latest settled
+34.13%
T+60 · $8.45
Vs SPY
+22.83%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 5 $6.30entry
  2. T+1 · 9mo ago +2.54%α +3.85% · $6.46
  3. T+5 · 8mo ago +1.59%α +3.82% · $6.40
  4. T+20 · 8mo ago +11.90%α +15.69% · $7.05
  5. T+60 · 6mo ago +34.13%α +22.83% · $8.45
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CorMedix reported strong Q4 and full-year 2025 results, driven by $128.6M in revenue (up 312% YoY) and $163.1M net income, a turnaround from a $17.9M loss in 2024. Growth was fueled by DefenCath sales and the full-quarter contribution from the Melinta acquisition. The company reiterated 2026 guidance and announced a $75M share repurchase program.

Key Financial Metrics

Revenue
$128.6M
+312.2% YoY
EPS
$0.16
Guidance
$300M-$320M
maintained

Key Facts

  • Q4 2025 net revenue was $128.6 million, up 312% from $31.2 million in Q4 2024
  • Full-year 2025 revenue was $311.7 million, with pro forma revenue of $401.3 million including Melinta
  • Q4 2025 net income was $14.0 million ($0.16 diluted EPS), compared to $13.5 million ($0.20 diluted EPS) in Q4 2024
  • Full-year 2025 net income was $163.1 million ($2.04 diluted EPS), versus a $17.9 million loss in 2024
  • Adjusted EBITDA was $77.2 million in Q4 2025, up from $15.3 million in Q4 2024
  • Company reiterated 2026 guidance: $300–$320M revenue and $100–$125M adjusted EBITDA
  • Announced $75 million share repurchase program
  • Cash and short-term investments totaled $148.5 million at year-end

Financial Impact

Revenue grew over 600% YoY, driven by acquisition and commercial execution. Net income swung from a $17.9M loss to $163.1M profit. Adjusted EBITDA nearly quintupled in Q4.

revenueepsnet_incomeebitdacash_flow

Risk Factors

  • Revenue growth heavily influenced by the Melinta acquisition; organic growth less clear
  • Q4 net income included a $42.4M tax expense tied to deferred tax assets, which may not repeat
  • 2026 guidance is flat to down on revenue despite strong 2025 results, suggesting near-term moderation

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3250043

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 5, 2026